[Preprint] Em estudo randomizado com 29.949 participantes, a vacina Novavax demonstrou alta eficácia geral (> 90%) na prevenção de Covid-19, e todos os casos moderados a graves ocorreram no grupo placebo.

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – medRxiv

Comentário: Novel vaccine demonstrates high efficacy for prevention of COVID-19 – News Medical

Contéudos relacionados:

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Comentário no Twitter

Remember Novavax's #COVID vaccine?

Recent data looks really good.

~30K participants enrolled in a prospective clinical trial.

The vaccine appeared to be safe & effective (>90%).

Unclear why approval is taking so long.

Preprint 👉 https://t.co/MQkJXdgJyR pic.twitter.com/217Erw2stC

— Isaac Bogoch (@BogochIsaac) October 12, 2021